Two novel determinants of etoposide resistance in small cell lung cancer

Cancer Research

Volumn 71, Issue 14, 2011, Pages 4877-4887

  Lawson, Malcolm H ^a,b   Cummings, Natalie M ^a,b   Rassl, Doris M ^b   Russell, Roslin ^a   Brenton, James D ^a   Rintoul, Robert C ^b   Murphy, Gillian ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DNA DIRECTED DNA POLYMERASE BETA; ETOPOSIDE; TRANSCRIPTION FACTOR NKX2.2;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL COUNT; CELL SURVIVAL; CHROMOSOME 2Q; CONTROLLED STUDY; DNA DAMAGE; DNA MICROARRAY; DRUG ACTIVITY; ENZYME INHIBITION; GENE DOSAGE; GENE OVEREXPRESSION; GENETIC IDENTIFICATION; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LUNG SMALL CELL CANCER; MOLECULAR CLONING; ONCOGENE; ONCOGENE NKX2.2; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DNA POLYMERASE BETA; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; GENE EXPRESSION; HOMEODOMAIN PROTEINS; HUMANS; LUNG NEOPLASMS; SMALL CELL LUNG CARCINOMA; TRANSCRIPTION FACTORS;

EID: 79960426035     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0080     Document Type: Article

References (41)

1. Lally BE, Geiger AM, Urbanic JJ, Butler JM, Wentworth S, Perry MC, et al. Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database. Lung Cancer 2009;64:226-31.
2. Amarasena IU, Walters JA, Wood-Baker R, Fong K. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev 2008;4:CD006849.
3. Huisman C, Postmus PE, Giaccone G, Smit EF. Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer Treat Rev 1999;25:199-206. (Pubitemid 29417677)
4. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 2003;4:181-9. (Pubitemid 37163832)
5. Giaccone G, Gazdar AF, Beck H, Zunino F, Capranico G. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 1992;52:1666-74.
6. Dingemans AM, Witlox MA, Stallaert RA, van der Valk P, Postmus PE, Giaccone G. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res 1999;5:2048-58. (Pubitemid 29399257)
7. Brock I, Hipfner DR, Nielsen BS, Jensen PB, Deeley RG, Cole SP, et al. Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res 1995;55:459-62.
8. Berendsen HH, de Leij L, de Vries EG, Mesander G, Mulder NH, de Jong B, et al. Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up. Cancer Res 1988;48:6891-9. (Pubitemid 19012223)
9. McCurrach ME, Connor TM, Knudson CM, Korsmeyer SJ, Lowe SW. Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci U S A 1997;94:2345-9. (Pubitemid 27136877)
10. Bengtsson H, Wirapati P, Speed TP. A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics 2009;25:2149-56.
11. Dunning MJ, Smith ML, Ritchie ME, Tavare S. Beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 2007;23:2183-4. (Pubitemid 47394121)
12. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and computational biology solutions using R and bioconductor. New York: Springer; 2005. p. 397-420.
13. Cairns JM, Dunning MJ, Ritchie ME, Russell R, Lynch AG. BASH: a tool for managing BeadArray spatial artefacts. Bioinformatics 2008;24:2921-2.
14. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502-16. (Pubitemid 37328838)
15. Sladek NE, Kollander R, Sreerama L, Kiang DT. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother Pharmacol 2002;49:309-21. (Pubitemid 34253270)
16. Hu HY, Horton JK, Gryk MR, Prasad R, Naron JM, Sun DA, et al. Identification of small molecule synthetic inhibitors of DNA polymerase beta by NMR chemical shift mapping. J Biol Chem 2004;279:39736-44. (Pubitemid 39258242)
17. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al. GammaH2AX and cancer. Nat Rev Cancer 2008;8:957-67.
18. Baillie-Johnson H, Twentyman PR, Fox NE, Walls GA, Workman P, Watson JV, et al. Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma). Br J Cancer 1985;52:495-504. (Pubitemid 16221570)
19. Lawson MH, Cummings NM, Rassl DM, Vowler SL, Wickens M, Howat WJ, et al. Bcl-2 and beta(1)-integrin predict survival in a tissue microarray of small cell lung cancer. Br J Cancer 2010;103:1710-5.
20. Hande KR, Wedlund PJ, Noone RM, Wilkinson GR, Greco FA, Wolff SN. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res 1984;44:379-82. (Pubitemid 14177767)
21. Cooke SL, Ng CK, Melnyk N, Garcia MJ, Hardcastle T, Temple J, et al. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene 2010;29:4905-13.
22. Rygaard K, Slebos RJ, Spang-Thomsen M. Radiosensitivity of small-cell lung cancer xenografts compared with activity of c-myc, N-myc, L-myc, c-raf-1 and K-ras proto-oncogenes. Int J Cancer 1991;49:279-84.
23. Batra RK, Warburton D. On the derivation and clinical implications of "driver" mutations in lung cancer. Am J Respir Crit Care Med 2010;182:4-5.
24. Vermeulen C, Verwijs-Janssen M, Cramers P, Begg AC, Vens C. Role for DNA polymerase beta in response to ionizing radiation. DNA Repair (Amst) 2007;6:202-12. (Pubitemid 46074494)
25. Horton JK, Baker A, Berg BJ, Sobol RW, Wilson SH. Involvement of DNA polymerase beta in protection against the cytotoxicity of oxidative DNA damage. DNA Repair (Amst) 2002;1:317-33.
26. Albertella MR, Lau A, O'Connor MJ. The overexpression of specialized DNA polymerases in cancer. DNA Repair (Amst) 2005;4:583-93. (Pubitemid 40462046)
27. Canitrot Y, Cazaux C, Frechet M, Bouayadi K, Lesca C, Salles B, et al. Overexpression of DNA polymerase beta in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs. Proc Natl Acad Sci U S A 1998;95:12586-90. (Pubitemid 28483808)
28. Iwatsuki M, Mimori K, Yokobori T, Tanaka F, Tahara K, Inoue H, et al. A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer. J Surg Oncol 2009;100:261-6.
29. Stachelek GC, Dalal S, Donigan KA, Campisi Hegan D, Sweasy JB, Glazer PM. Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase beta is accentuated by BRCA2 mutation. Cancer Res 2010;70:409-17.
30. Neijenhuis S, Verwijs-Janssen M, Kasten-Pisula U, Rumping G, Borgmann K, Dikomey E, et al. Mechanism of cell killing after ionizing radiation by a dominant negative DNA polymerase beta. DNA Repair (Amst) 2009;8:336-46.
31. Bromberg KD, Burgin AB, Osheroff N. A two-drug model for etoposide action against human topoisomerase IIalpha. J Biol Chem 2003;278:7406-12. (Pubitemid 36800745)
32. Muslimovic A, Nystrom S, Gao Y, Hammarsten O. Numerical analysis of etoposide induced DNA breaks. PLoS One 2009;4:e5859.
33. Long BH, Musial ST, Brattain MG. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide. Cancer Res 1986;46:3809-16. (Pubitemid 16075866)
34. Tounekti O, Kenani A, Foray N, Orlowski S, Mir LM. The ratio of single-to double-strand DNA breaks and their absolute values determine cell death pathway. Br J Cancer 2001;84:1272-9. (Pubitemid 32511347)
35. Qi Y, Cai J, Wu Y, Wu R, Lee J, Fu H, et al. Control of oligodendrocyte differentiation by the Nkx2.2 homeodomain transcription factor. Development 2001;128:2723-33. (Pubitemid 32701001)
36. Sussel L, Kalamaras J, Hartigan-O'Connor DJ, Meneses JJ, Pedersen RA, Rubenstein JL, et al. Mice lacking the homeodomain transcription factor Nkx2.2 have diabetes due to arrested differentiation of pancreatic beta cells. Development 1998;125:2213-21. (Pubitemid 28336383)
37. Wang CC, Brodnicki T, Copeland NG, Jenkins NA, Harvey RP. Conserved linkage of NK-2 homeobox gene pairs Nkx2-2/2-4 and Nkx2-1/2-9 in mammals. Mamm Genome 2000;11:466-8. (Pubitemid 30407412)
38. Hsu DS, Acharya CR, Balakumaran BS, Riedel RF, Kim MK, Stevenson M, et al. Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proc Natl Acad Sci U S A 2009;106:5312-7.
39. Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS One 2008;3:e1965.
40. Gupta A, Wang Y, Browne C, Kim S, Case T, Paul M, et al. Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells. Prostate 2008;68:50-60.
41. Wang YC, Gallego-Arteche E, Iezza G, Yuan X, Matli MR, Choo SP, et al. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors. Endocr Relat Cancer 2009;16:267-79.